189 related articles for article (PubMed ID: 31477804)
1. Oncolytic activity of HF10 in head and neck squamous cell carcinomas.
Esaki S; Goshima F; Ozaki H; Takano G; Hatano Y; Kawakita D; Ijichi K; Watanabe T; Sato Y; Murata T; Iwata H; Shibamoto Y; Murakami S; Nishiyama Y; Kimura H
Cancer Gene Ther; 2020 Aug; 27(7-8):585-598. PubMed ID: 31477804
[TBL] [Abstract][Full Text] [Related]
2. Combination treatment of human pancreatic cancer xenograft models with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and oncolytic herpes simplex virus HF10.
Yamamura K; Kasuya H; Sahin TT; Tan G; Hotta Y; Tsurumaru N; Fukuda S; Kanda M; Kobayashi D; Tanaka C; Yamada S; Nakayama G; Fujii T; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Tanaka M; Kodera Y
Ann Surg Oncol; 2014 Feb; 21(2):691-8. PubMed ID: 24170435
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma.
Takano G; Esaki S; Goshima F; Enomoto A; Hatano Y; Ozaki H; Watanabe T; Sato Y; Kawakita D; Murakami S; Murata T; Nishiyama Y; Iwasaki S; Kimura H
Mol Ther Oncolytics; 2021 Mar; 20():220-227. PubMed ID: 33665360
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10.
Watanabe D; Goshima F; Mori I; Tamada Y; Matsumoto Y; Nishiyama Y
J Dermatol Sci; 2008 Jun; 50(3):185-96. PubMed ID: 18226503
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus.
Kohno SI; Luo C; Nawa A; Fujimoto Y; Watanabe D; Goshima F; Tsurumi T; Nishiyama Y
Cancer Gene Ther; 2007 Nov; 14(11):918-26. PubMed ID: 17693992
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
Fujimoto Y; Mizuno T; Sugiura S; Goshima F; Kohno S; Nakashima T; Nishiyama Y
Acta Otolaryngol; 2006 Oct; 126(10):1115-7. PubMed ID: 16923721
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Esaki S; Goshima F; Kimura H; Murakami S; Nishiyama Y
Int J Cancer; 2013 Apr; 132(7):1592-601. PubMed ID: 22949155
[TBL] [Abstract][Full Text] [Related]
8. Sentinel Lymph Node-Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model.
Tanaka Y; Araki K; Tanaka S; Miyagawa Y; Suzuki H; Kamide D; Tomifuji M; Uno K; Kimura E; Yamashita T; Ueda Y; Shiotani A
Mol Cancer Ther; 2019 Aug; 18(8):1430-1438. PubMed ID: 31171582
[TBL] [Abstract][Full Text] [Related]
9. [Oncolytic virotherapy using replication-competent herpes simplex viruses].
Nishiyama Y; Goshima F
Uirusu; 2007 Jun; 57(1):57-65. PubMed ID: 18040155
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of oncolytic herpes simplex virus HF10 and bevacizumab against experimental model of human breast carcinoma xenograft.
Tan G; Kasuya H; Sahin TT; Yamamura K; Wu Z; Koide Y; Hotta Y; Shikano T; Yamada S; Kanzaki A; Fujii T; Sugimoto H; Nomoto S; Nishikawa Y; Tanaka M; Tsurumaru N; Kuwahara T; Fukuda S; Ichinose T; Kikumori T; Takeda S; Nakao A; Kodera Y
Int J Cancer; 2015 Apr; 136(7):1718-30. PubMed ID: 25156870
[TBL] [Abstract][Full Text] [Related]
11. Lister vaccine strain of vaccinia virus armed with the endostatin-angiostatin fusion gene: an oncolytic virus superior to dl1520 (ONYX-015) for human head and neck cancer.
Tysome JR; Wang P; Alusi G; Briat A; Gangeswaran R; Wang J; Bhakta V; Fodor I; Lemoine NR; Wang Y
Hum Gene Ther; 2011 Sep; 22(9):1101-8. PubMed ID: 21361787
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus type 1 mutant HF10 oncolytic viral therapy for bladder cancer.
Kohno S; Luo C; Goshima F; Nishiyama Y; Sata T; Ono Y
Urology; 2005 Nov; 66(5):1116-21. PubMed ID: 16286150
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
14. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
Teshigahara O; Goshima F; Takao K; Kohno S; Kimata H; Nakao A; Nishiyama Y
J Surg Oncol; 2004 Jan; 85(1):42-7. PubMed ID: 14696086
[TBL] [Abstract][Full Text] [Related]
16. Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.
Hamada M; Yura Y
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992948
[TBL] [Abstract][Full Text] [Related]
17. The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.
Tanaka R; Goshima F; Esaki S; Sato Y; Murata T; Nishiyama Y; Watanabe D; Kimura H
Am J Cancer Res; 2017; 7(8):1693-1703. PubMed ID: 28861325
[TBL] [Abstract][Full Text] [Related]
18. Phase I Dose-escalation Clinical Trial of HF10 Oncolytic Herpes Virus in 17 Japanese Patients with Advanced Cancer.
Kasuya H; Kodera Y; Nakao A; Yamamura K; Gewen T; Zhiwen W; Hotta Y; Yamada S; Fujii T; Fukuda S; Tsurumaru N; Kuwahara T; Kikumori T; Koide Y; Fujimoto Y; Nakashima T; Hirooka Y; Shiku H; Tanaka M; Takesako K; Kondo T; Aleksic B; Kawashima H; Goto H; Nishiyama Y
Hepatogastroenterology; 2014 May; 61(131):599-605. PubMed ID: 26176043
[TBL] [Abstract][Full Text] [Related]
19. Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Shimoyama S; Goshima F; Teshigahara O; Kasuya H; Kodera Y; Nakao A; Nishiyama Y
Hepatogastroenterology; 2007 Jun; 54(76):1038-42. PubMed ID: 17629034
[TBL] [Abstract][Full Text] [Related]
20. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
